Home | Welcome to Contract Pharma   
Last Updated Wednesday, May 22 2013
Print

Collaborations & Alliances

Related Searches:

Filter by:

April 11, 2013
Dalton to synthesize and manufacture selected drug candidates   Read More »
April 10, 2013
Adds Anticalin program   Read More »
April 9, 2013
Acquires rights to Tykerb in China   Read More »
April 8, 2013
Regains all commercialization rights   Read More »
April 5, 2013
Will use conjugation technology to develop ADCs in oncology   Read More »
April 5, 2013
Will evaluate VX-135 and daclatasvir in hepatitis C   Read More »
April 4, 2013
To develop novel antibody program from X-BODY platform   Read More »
April 4, 2013
To develop CHO cell lines and assess product attributes for proteins   Read More »
April 3, 2013
Gains access to Captisol technology   Read More »
April 3, 2013
Will develop and commercialize multiple Accurins   Read More »
April 2, 2013
Will use Tetragenetics technology platform for antibody production   Read More »
April 2, 2013
Extreme Diversity platform will help develop candidates   Read More »
April 2, 2013
SK to develop and commercialize THVD-201 and THVD-202   Read More »
March 28, 2013
Aims to identify new approaches to metabolic disease   Read More »
March 28, 2013
Receives $35 mil. upfront for orphan treatments   Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On